ADAM17—A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer

ADAM17—A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer

Ovarian cancer has the highest mortality rate among gynecological tumors. This is based on late diagnosis and the lack of early symptoms. To improve early detection, it is essential to find reliable biomarkers. The metalloprotease ADAM17 could be a potential marker, as it is highly expressed in many...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Christoph Rogmans, Jan Dominik Kuhlmann, Gerrit Hugendieck, Theresa Link, Norbert Arnold, Jörg Paul Weimer, Inken Flörkemeier, Anna-Christina Rambow, Wolfgang Lieb, Nicolai Maass, Dirk O. Bauerschlag, Nina Hedemann
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
ovarian cancer
ADAM17
serum
ascites
tumor marker
early detection
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/4e1ccf5ac3f349e3bb09092653ec41ae
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/4e1ccf5ac3f349e3bb09092653ec41ae

Ejemplares similares